

**Reference:** FOI.ICB-2526/282

**Subject:** Use of GLP-1 and Other Diabetes and Weight Loss Medications in Prisons

*I can confirm that the ICB does not hold the information requested; please see responses below:*

QUESTION	RESPONSE
<p>The purpose of this request is to gather data on the use of GLP-1 agonists and other diabetes and weight loss medications prescribed across the prison population.</p> <p>I am seeking anonymised, aggregate information covering the period January 2020 to October 2025.</p>	
<p>1. Via your ICB, the total number of prescriptions dispensed across the prison population for the following medications, broken down by year: Victoza (Liraglutide), Ozempic (Semaglutide), Rybelsus (Semaglutide), Trulicity (Dulaglutide), Bydureon (Exenatide), and Mounjaro (Tirzepatide)</p>	<p>The ICB does not hold this information.</p> <p>NHS England commissions prison healthcare, therefore, we advise you to contact them for the information; <a href="https://www.england.nhs.uk/contact-us/foi/">https://www.england.nhs.uk/contact-us/foi/</a></p>
<p>2. Via your ICB, the total number of prescriptions dispensed across the prison population for the following medications, broken down by year: Saxenda (Liraglutide), Wegovy (Semaglutide), Orlistat (Xenical / Alli) and Mysimba (Naltrexone / Bupropion)</p>	

***The information provided in this response is accurate as of 21 November 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.***